{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:51:29Z","timestamp":1790128289400,"version":"4.0.1"},"reference-count":63,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","annallergy.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.anai.2024.05.020","type":"journal-article","created":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T15:41:24Z","timestamp":1718466084000},"page":"367-373","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["The future of targeted therapy in chronic spontaneous urticaria"],"prefix":"10.1016","volume":"133","author":[{"given":"Taek Ki","family":"Min","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8522-2742","authenticated-orcid":false,"given":"Sarbjit S.","family":"Saini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2024.05.020_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2022.840999","article-title":"Acute urticaria and anaphylaxis: differences and similarities in clinical management","volume":"3","author":"Ensina","year":"2022","journal-title":"Front Allergy"},{"issue":"3","key":"10.1016\/j.anai.2024.05.020_bib0002","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/all.15090","article-title":"The international EAACI\/GA(2)LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria","volume":"77","author":"Zuberbier","year":"2022","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.anai.2024.05.020_bib0003","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jaip.2023.11.029","article-title":"Comorbid inducible urticaria is linked to non-autoimmune chronic spontaneous urticaria: CURE insights","volume":"12","author":"Kovalkova","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.anai.2024.05.020_bib0004","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s40271-015-0145-9","article-title":"The impact of chronic urticaria from the Patient's perspective: a survey in five European countries","volume":"8","author":"Balp","year":"2015","journal-title":"Patient"},{"issue":"8","key":"10.1016\/j.anai.2024.05.020_bib0005","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/j.1365-2230.2010.03840.x","article-title":"Epidemiology of urticaria: a representative cross-sectional population survey","volume":"35","author":"Zuberbier","year":"2010","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2024.05.020_bib0006","doi-asserted-by":"crossref","first-page":"438","DOI":"10.4168\/aair.2017.9.5.438","article-title":"Epidemiology of chronic urticaria in Korea using the Korean health insurance database, 2010-2014","volume":"9","author":"Lee","year":"2017","journal-title":"Allergy Asthma Immunol Res"},{"issue":"5","key":"10.1016\/j.anai.2024.05.020_bib0007","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S1081-1206(10)60360-2","article-title":"Effect of arterial hypertension on chronic urticaria duration","volume":"103","author":"Nebiolo","year":"2009","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/j.anai.2024.05.020_bib0008","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1346-8138.2007.00276.x","article-title":"Chronic idiopathic urticaria: prevalence and clinical course","volume":"34","author":"Kulthanan","year":"2007","journal-title":"J Dermatol"},{"issue":"8","key":"10.1016\/j.anai.2024.05.020_bib0009","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/j.1398-9995.2004.00473.x","article-title":"Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients","volume":"59","author":"Toubi","year":"2004","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.anai.2024.05.020_bib0010","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41572-022-00389-z","article-title":"Urticaria","volume":"8","author":"Kolkhir","year":"2022","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.anai.2024.05.020_bib0011","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s13555-021-00641-6","article-title":"Clinical remission of chronic spontaneous urticaria (CSU): a targeted literature review","volume":"12","author":"Balp","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.anai.2024.05.020_bib0012","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13601-017-0141-3","article-title":"Effectiveness and safety of antihistamines up to 4-fold or higher in treatment of chronic spontaneous urticaria","volume":"7","author":"van den Elzen","year":"2017","journal-title":"Clin Transl Allergy"},{"issue":"6","key":"10.1016\/j.anai.2024.05.020_bib0013","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/bjd.14768","article-title":"Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis","volume":"175","author":"Guillen-Aguinaga","year":"2016","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2024.05.020_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2011.06.010","article-title":"A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria","volume":"128","author":"Saini","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.anai.2024.05.020_bib0015","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.anai.2024.05.020_bib0016","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2013.05.013","article-title":"Omalizumab in patients with symptomatic chronic idiopathic\/spontaneous urticaria despite standard combination therapy","volume":"132","author":"Kaplan","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2024.05.020_bib0017","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/jid.2014.306","article-title":"Efficacy and safety of omalizumab in patients with chronic idiopathic\/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study","volume":"135","author":"Saini","year":"2015","journal-title":"J Investig Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2024.05.020_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2015.04.015","article-title":"Similar efficacy with omalizumab in chronic idiopathic\/spontaneous urticaria despite different background therapy","volume":"3","author":"Casale","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"suppl 5","key":"10.1016\/j.anai.2024.05.020_bib0019","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/jdv.13697","article-title":"Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria","volume":"30","author":"Gimenez-Arnau","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.anai.2024.05.020_bib0020","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.jaip.2019.10.018","article-title":"High-dose omalizumab use in patients with chronic spontaneous urticaria","volume":"8","author":"Alizadeh Aghdam","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2024.05.020_bib0021","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41467-019-13815-w","article-title":"The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab","volume":"11","author":"Gasser","year":"2020","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.anai.2024.05.020_bib0022","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/cea.12400","article-title":"Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects","volume":"44","author":"Arm","year":"2014","journal-title":"Clin Exp Allergy"},{"issue":"14","key":"10.1016\/j.anai.2024.05.020_bib0023","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1900408","article-title":"Ligelizumab for chronic spontaneous urticaria","volume":"381","author":"Maurer","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.anai.2024.05.020_bib0024","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1111\/all.15175","article-title":"Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: a one-year extension study","volume":"77","author":"Maurer","year":"2022","journal-title":"Allergy"},{"issue":"10422","key":"10.1016\/j.anai.2024.05.020_bib0025","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0140-6736(23)01684-7","article-title":"Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials","volume":"403","author":"Maurer","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.anai.2024.05.020_bib0026","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/antib11010017","article-title":"Immune- and non-immune-mediated adverse effects of monoclonal antibody therapy: a survey of 110 approved antibodies","volume":"11","author":"Baldo","year":"2022","journal-title":"Antibodies (Basel)"},{"issue":"3","key":"10.1016\/j.anai.2024.05.020_bib0027","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/1744666X.2023.2268291","article-title":"A critical review of dupilumab for adult patients with prurigo nodularis","volume":"20","author":"Biazus Soares","year":"2024","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2024.05.020_bib0028","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1067\/mai.2002.123236","article-title":"TH1\/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: comparison with the allergen-induced late-phase cutaneous reaction","volume":"109","author":"Ying","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2024.05.020_bib0029","article-title":"Long-term follow-up of patients treated with dupilumab for chronic spontaneous urticaria: a case report","volume":"10","author":"Abadeh","year":"2022","journal-title":"SAGE Open Med Case Rep"},{"issue":"2","key":"10.1016\/j.anai.2024.05.020_bib0030","doi-asserted-by":"crossref","first-page":"AB312","DOI":"10.1016\/j.jaci.2021.12.002","article-title":"Dupilumab significantly reduces itch and hives in patients with chronic spontaneous urticaria: results from a Phase 3 trial (Liberty-CSU CUPID Study A)","volume":"149","author":"Maurer","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2024.05.020_bib0031","doi-asserted-by":"crossref","unstructured":"Maurer M, Casale TB, Saini SS, Ben-Shoshan M, Gim\u00e9nez-Arnau AM, Bernstein JA, et al. Dupilumab in patients with chronic spontaneous urticaria (Liberty-CSU CUPID): two randomized, double-blind, placebo-controlled, phase 3 trials [e-pub ahead of print]. J Allergy Clin Immunol. https:\/\/doi.org\/10.1016\/j.jaci.2024.01.028, accessed February 2, 2024.","DOI":"10.1016\/j.jaci.2024.01.028"},{"key":"10.1016\/j.anai.2024.05.020_bib0032","unstructured":"Sanofi. Update on ongoing Dupixent\u00ae (dupilumab) chronic spontaneous urticaria phase 3 program. Accessed February 2, 2024. Available at: https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2022\/2022-02-18-06-00-00-2387700"},{"key":"10.1016\/j.anai.2024.05.020_bib0033","unstructured":"Sanofi. Media update: Sanofi and Regeneron provide update on Dupixent\u00ae (dupilumab) sBLA for Chronic Spontaneous urticaria. Accessed February 2, 2024. Available at: https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2023\/2023-10-20-21-00-00-2764252"},{"key":"10.1016\/j.anai.2024.05.020_bib0034","unstructured":"Sanofi. Press Release: Japan first in the world to approve Dupixent\u00ae for chronic spontaneous urticaria (CSU). Accessed February 2, 2024. Available at: https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2024\/2024-02-16-06-00-00-2830509"},{"issue":"3","key":"10.1016\/j.anai.2024.05.020_bib0035","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/bjd.12991","article-title":"Elevations in vascular markers and eosinophils in chronic spontaneous urticarial weals with low-level persistence in uninvolved skin","volume":"171","author":"Kay","year":"2014","journal-title":"Br J Dermatol"},{"issue":"14","key":"10.1016\/j.anai.2024.05.020_bib0036","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1056\/NEJMc2016395","article-title":"Benralizumab for chronic spontaneous urticaria","volume":"383","author":"Bernstein","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2024.05.020_bib0037","doi-asserted-by":"crossref","unstructured":"Altrichter S, Gimenez-Arnau AM, Bernstein JA, Metz M, Bahadori L, Bergquist M, et al. Benralizumab does not elicit therapeutic effect in patients with chronic spontaneous urticaria: results from the phase 2b multinational, randomised, double-blind, placebo-controlled ARROYO trial [e-pub ahead of print]. Br J Dermatol. https:\/\/doi.org\/10.1093\/bjd\/ljae067, accessed February 4, 2024.","DOI":"10.1093\/bjd\/ljae067"},{"issue":"5","key":"10.1016\/j.anai.2024.05.020_bib0038","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/bjd.13621","article-title":"Elevations in T-helper-2-initiating cytokines (interleukin-33, interleukin-25 and thymic stromal lymphopoietin) in lesional skin from chronic spontaneous (\u2018idiopathic\u2019) urticaria","volume":"172","author":"Kay","year":"2015","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.anai.2024.05.020_bib0039","first-page":"AB373","article-title":"Sustained Improvement in UAS7 after 16-week Treatment with Tezepelumab in Biologic-Na\u00efve Adults with CSU: results of the Phase 2b INCEPTION Study","volume":"153","author":"Maurer","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2024.05.020_bib0040","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nri2056","article-title":"Siglecs and their roles in the immune system","volume":"7","author":"Crocker","year":"2007","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/j.anai.2024.05.020_bib0041","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.anai.2019.08.465","article-title":"Current and emerging treatments for chronic spontaneous urticaria","volume":"125","author":"Johal","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/j.anai.2024.05.020_bib0042","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.jaci.2021.12.772","article-title":"An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria","volume":"149","author":"Altrichter","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2024.05.020_bib0043","unstructured":"Allakos Investors. Allakos announces Phase 2 lirentelimab trials in atopic dermatitis and chronic spontaneous urticaria did not meet their primary endpoints. Accessed February 2, 2024. Available at: https:\/\/investor.allakos.com\/news-releases\/news-release-details\/allakos-announces-phase-2-lirentelimab-trials-atopic-dermatitis"},{"issue":"5","key":"10.1016\/j.anai.2024.05.020_bib0044","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.jaci.2023.12.008","article-title":"BTK signaling-a crucial link in the pathophysiology of chronic spontaneous urticaria","volume":"153","author":"Bernstein","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"10.1016\/j.anai.2024.05.020_bib0045","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1038\/s41591-021-01537-w","article-title":"Fenebrutinib in H(1) antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial","volume":"27","author":"Metz","year":"2021","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.anai.2024.05.020_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2022.08.027","article-title":"Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria","volume":"150","author":"Maurer","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2024.05.020_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2021.12.589","article-title":"Remibrutinib treatment improves quality of life in patients with chronic spontaneous urticaria","volume":"149","author":"Maurer","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2024.05.020_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2023.10.007","article-title":"Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks","volume":"153","author":"Jain","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2024.05.020_bib0049","doi-asserted-by":"crossref","first-page":"S230","DOI":"10.1016\/j.anai.2023.10.019","article-title":"Fast symptom improvement and favorable safety profile with remibrutinib in chronic spontaneous urticaria: Remix-1\/-2 studies","volume":"131","author":"Saini","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"7","key":"10.1016\/j.anai.2024.05.020_bib0050","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.4049\/jimmunol.2001130","article-title":"Preclinical efficacy and anti-inflammatory mechanisms of action of the Bruton tyrosine kinase inhibitor rilzabrutinib for immune-mediated disease","volume":"206","author":"Langrish","year":"2021","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.anai.2024.05.020_bib0051","first-page":"AB373","article-title":"Efficacy and safety of rilzabrutinib in patients with chronic spontaneous urticaria: 12-week results from the RILECSU phase 2 dose-ranging study","volume":"153","author":"Maurer","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.anai.2024.05.020_bib0052","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/j.jaip.2022.09.038","article-title":"Existing and investigational medications for refractory chronic spontaneous urticaria: safety, adverse effects, and monitoring","volume":"10","author":"Kocaturk","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.anai.2024.05.020_bib0053","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/all.15585","article-title":"Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria","volume":"78","author":"Terhorst-Molawi","year":"2023","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.anai.2024.05.020_bib0054","doi-asserted-by":"crossref","first-page":"AB133","DOI":"10.1016\/j.jaci.2022.12.418","article-title":"Safety and clinical activity of multiple doses of barzolvolimab, an anti-KIT antibody, in patients with chronic spontaneous urticaria","volume":"151","author":"Maurer","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2024.05.020_bib0055","doi-asserted-by":"crossref","first-page":"AB366","DOI":"10.1016\/j.jaci.2023.11.873","article-title":"Barzolvolimab significantly decreases chronic spontaneous urticaria disease activity and is well tolerated: top line results from a Phase 2 trial","volume":"153","author":"Maurer","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2024.05.020_bib0056","doi-asserted-by":"crossref","first-page":"AB62","DOI":"10.1016\/j.jaci.2023.11.215","article-title":"BLU-808, a potent and selective small molecule inhibitor of wild-type c-KIT for mast cell disorders","volume":"153","author":"Grassian","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2024.05.020_bib0057","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jaci.2020.08.027","article-title":"Mas-related G protein-coupled receptor X2 and its activators in dermatologic allergies","volume":"147","author":"Kuhn","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2024.05.020_bib0058","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jaci.2014.05.004","article-title":"Expression of Mas-related gene X2 on mast cells is upregulated in the skin of patients with severe chronic urticaria","volume":"134","author":"Fujisawa","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2024.05.020_bib0059","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.jid.2020.06.030","article-title":"MRGPRX2 activation causes increased skin reactivity in patients with chronic spontaneous urticaria","volume":"141","author":"Shtessel","year":"2021","journal-title":"J Investig Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2024.05.020_bib0060","doi-asserted-by":"crossref","first-page":"498","DOI":"10.4168\/aair.2021.13.3.498","article-title":"Elevated MRGPRX2 levels related to disease severity in patients with chronic spontaneous urticaria","volume":"13","author":"Cao","year":"2021","journal-title":"Allergy Asthma Immunol Res"},{"issue":"7","key":"10.1016\/j.anai.2024.05.020_bib0061","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.3390\/cells11071138","article-title":"Functional and phenotypic characterization of Siglec-6 on human mast cells","volume":"11","author":"Robida","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.anai.2024.05.020_bib0062","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jaci.2022.07.018","article-title":"Expression and regulation of Siglec-6 (CD327) on human mast cells and basophils","volume":"151","author":"Smiljkovic","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2024.05.020_bib0063","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/s42003-022-04207-w","article-title":"Discovery of an agonistic Siglec-6 antibody that inhibits and reduces human mast cells","volume":"5","author":"Schanin","year":"2022","journal-title":"Commun Biol"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120624003430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120624003430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T07:35:04Z","timestamp":1738136104000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120624003430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1081120624003430"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2024.05.020","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The future of targeted therapy in chronic spontaneous urticaria","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2024.05.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}